Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Terry L NgD Ross Camidge

Abstract

We evaluated pulmonary adverse events observed within 7 days after drug initiation in phase 1 to phase 3 studies of the anaplastic lymphoma kinase (ALK) inhibitor brigatinib. The phase 1/2 study enrolled patients with advanced malignancies (dosage range, 30 mg-300 mg once a day); the phase 2 ALK in Lung Cancer Trial of AP26113 study treated patients with advanced ALK+ NSCLC postcrizotinib at either 90 mg once a day or 90 mg once a day for 7 days followed by 180 mg once a day; and the phase 3 ALK in Lung Cancer Trial of Brigatinib in first Line study treated inhibitor-naive patients with ALK+ NSCLC with brigatinib (180 mg once a day [with 7-day lead-in at 90 mg once a day]) or crizotinib (250 mg twice a day). Early-onset pulmonary events (EOPEs) at least possibly associated with brigatinib were captured. In the phase 1/2, ALK in Lung Cancer Trial of AP26113, and ALK in Lung Cancer Trial of Brigatinib in first Line studies, 8% (11/137), 6% (14/219), and 3% (4/136) of patients, respectively, had at least possible EOPEs on brigatinib, with frequency appearing to increase with the starting dosage. Across trials, at the 90-mg once-a-day starting dosage (alone or step-up dosing), 4.5% of patients (20/440) had at least possible events ...Continue Reading

References

Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
Mar 12, 2013·Pharmacological Reviews·Jack Uetrecht, Dean J Naisbitt
May 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dong-Wan KimD Ross Camidge
Oct 4, 2018·The New England Journal of Medicine·D Ross CamidgeSanjay Popat
May 21, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·D Ross CamidgeLyudmila Bazhenova

❮ Previous
Next ❯

Citations

Aug 21, 2020·Clinical Pharmacokinetics·Neeraj GuptaKarthik Venkatakrishnan
Dec 12, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Terry L NgErin L Schenk
Jan 27, 2021·Pharmaceuticals·Mei Elsayed, Petros Christopoulos
Nov 29, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Makoto NishioNobuyuki Yamamoto
Mar 31, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Misako Nagasaka, Sai-Hong Ignatius Ou
Apr 4, 2021·Cancers·Sara CherriAlberto Zaniboni
Jul 1, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Herbert H LoongYat-Ming Lau

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Annals of Pharmacotherapy
Sara A SpencerAnthony J Di Pasqua
Annals of Oncology : Official Journal of the European Society for Medical Oncology
F GomesY Summers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sen ZhangVictor M Rivera
© 2021 Meta ULC. All rights reserved